RapiMeds has always been on the back burner. What kept me excited about RapiMeds is that Mr. Schneiderman never gave up on this product. It's just taken longer than expected to bring it to fruition. Combine RapiMeds potential revenues with our current compounding ever growing potential and I believe we are looking at a $100M+ company. 2015 will be one incredible and exciting year for all the SCRC investors.